Temozolomide (Temodar)
- PMID: 20538821
- PMCID: PMC7966084
- DOI: 10.3174/ajnr.A2170
Temozolomide (Temodar)
Abstract
Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.
Figures


Similar articles
-
Temozolomide. A new option for high-grade astrocytomas.Cancer Pract. 2000 Nov-Dec;8(6):311-3. doi: 10.1046/j.1523-5394.2000.86004.x. Cancer Pract. 2000. PMID: 11898150 Review. No abstract available.
-
NICE verdict on Temozolomide: where next?Br J Cancer. 2002 Feb 12;86(4):499-500. doi: 10.1038/sj.bjc.6600134. Br J Cancer. 2002. PMID: 11870526 Free PMC article.
-
Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.J Neurooncol. 2006 Apr;77(2):219-20. doi: 10.1007/s11060-005-9019-7. Epub 2005 Nov 15. J Neurooncol. 2006. PMID: 16292485 No abstract available.
-
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.Intern Med J. 2002 Jul;32(7):346-8. doi: 10.1046/j.1445-5994.2002.00242.x. Intern Med J. 2002. PMID: 12088355
-
Temozolomide in malignant gliomas.Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34. Semin Oncol. 2000. PMID: 10866347 Review.
Cited by
-
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.Dig Dis Sci. 2013 May;58(5):1415-21. doi: 10.1007/s10620-012-2493-9. Epub 2012 Dec 5. Dig Dis Sci. 2013. PMID: 23212393 Free PMC article. Review.
-
CRISPR-Cas System Is an Effective Tool for Identifying Drug Combinations That Provide Synergistic Therapeutic Potential in Cancers.Cells. 2023 Nov 9;12(22):2593. doi: 10.3390/cells12222593. Cells. 2023. PMID: 37998328 Free PMC article. Review.
-
Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity.Cancer Treat Res. 2023;190:95-142. doi: 10.1007/978-3-031-45654-1_4. Cancer Treat Res. 2023. PMID: 38113000
-
Autophagy modulates temozolomide-induced cell death in alveolar Rhabdomyosarcoma cells.Cell Death Discov. 2018 Oct 25;4:52. doi: 10.1038/s41420-018-0115-9. eCollection 2018. Cell Death Discov. 2018. PMID: 30416757 Free PMC article.
-
Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier.Front Immunol. 2023 Feb 17;14:1057567. doi: 10.3389/fimmu.2023.1057567. eCollection 2023. Front Immunol. 2023. PMID: 36875096 Free PMC article. Review.
References
-
- Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 2009;64:647–55 - PubMed
-
- Colvin M. Alkylating agents and platinum antitumor compounds. In: Kufe DW, Frei E, Holland JF, et al. eds. Holland-Frei Cancer Medicine. 8th ed. Shelton, Connecticut: People's Medical Publishing House; 2010
-
- Newlands ES, Stevens MF, Wedge SR, et al. . Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35–61 - PubMed
-
- Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144–51 - PubMed
-
- Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585–97 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical